Articles tagged with Ovarian Cancer
Researchers at MUSC and UCSD found that autophagy genes work against tumors in certain types of ovarian cancer. The study validated the role of BECN1 and LC3B as tumor suppressors, shedding light on their potential as targets for treatment.
Researchers at the University of Oxford have identified six previously unknown cell types in human Fallopian tubes using single-cell RNA sequencing, which may lead to a screening tool for ovarian cancer. The discovery sheds new light on the complexity of ovarian cancers and could lead to personalized treatments.
A Phase 2 clinical trial demonstrated improved localization and complete removal of small and peripheral lesions in 12% of patients. The treatment, OTL38, targets adenocarcinomas of the lung and has received fast-track designation for both lung and ovarian cancer indications.
Scientists discovered that over 20% of mutations occur in early stages of tumor development, with some changes taking place years or even decades before cancer is diagnosed. These early genetic alterations can be identified using a new method developed by researchers at the Francis Crick Institute.
A new MRI tool has been developed and shown to be 90% accurate in distinguishing between malignant and benign ovarian cysts. This could lead to earlier treatment and improved outcomes for women with ovarian cancer, reducing the need for invasive surgery.
A study found that APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab. The researchers also identified a distinct gene signature associated with resistance development, paving the way for new treatment strategies.
Researchers pooled data from four large studies involving 250,000 women to investigate the association between powder use and ovarian cancer risk. The study found a statistically significant increase in ovarian cancer risk among women who used powder in their genital area.
Researchers have identified a new therapeutic strategy to combat chemotherapy resistance in ovarian cancer by targeting the NAD+ metabolic pathway. Combining cisplatin treatment with pharmacological inhibition of NAMPT suppresses the outgrowth of resistant cancer cells and prolongs survival in a preclinical model.
Researchers at the University of Texas MD Anderson Cancer Center found that secondary tumor-reduction surgery followed by chemotherapy did not result in longer survival than chemotherapy alone. The study involved 240 patients with platinum-sensitive recurrent ovarian cancer and showed that complete tumor resection was associated with i...
Nami Therapeutics develops nanoparticles for targeted drug delivery, offering increased efficacy and reduced toxicity. The platform selectively targets ovarian cancer metastasis in the peritoneal cavity, improving survival rates.
A new study found that a blood test for CA125 levels can detect ovarian cancer in women with suspicious symptoms, with 10% of those with high levels diagnosed with the disease. The test also revealed higher risks of other cancers, such as pancreatic and lung cancer, among older women
A laboratory study found that fibrosis, a natural stiffening of the ovaries, occurs with age and may be linked to ovarian cancer. Metformin, a diabetes drug, was shown to halt this process in some cases.
A new treatment using niraparib after conventional chemotherapy improves progression-free survival and reduces risk of relapse or death in patients with advanced ovarian cancer. The study, led by Dr. Antonio González Martín, found a significant reduction in risk of relapse, especially in patients with homologous recombination deficiency.
A new trial shows that adding a PARP inhibitor to bevacizumab improves ovarian cancer patients' chances of responding to chemotherapy. The study found median progression-free survival of 22.1 months in the olaparib arm, compared to 16.6 months in the placebo group.
A Phase III trial validates the benefit of veliparib for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. The combination therapy achieved a PFS of 23.5 months, compared to 17.3 months for the control arm.
Cancer survival in the UK has improved since 1995, with significant increases in one-year and five-year survival rates for various cancers. Despite this progress, the UK still lags behind other high-income countries in cancer survival.
Survival rates for seven cancers have improved in Australia, Canada, and Norway compared to New Zealand, Denmark, Ireland, and the UK. The largest gains were seen in patients under 75 years old with poor prognosis cancers. Improvements in cancer control suggest progress has been made in these countries.
Researchers at The Wistar Institute have found that ARID1A is essential for telomere cohesion, which helps maintain genomic stability. Inactivation of ARID1A leads to loss of telomere cohesion and selects against gross chromosome alterations.
A new study found that women who experienced PTSD symptoms were at a higher risk of developing ovarian cancer, particularly those with high-grade serous histotype. Researchers analyzed data from the Nurses' Health Study II and found a significant association between PTSD and increased ovarian cancer risk.
A new study links elevated levels of FAK to the survival of cancer stem cells and DNA repair in ovarian cancer tumors, making them resistant to platinum chemotherapy. Researchers found that FAK inhibition can improve treatment response in mice with chemo-resistant tumors.
The USPSTF recommends assessing risk in women with a history of breast, ovarian, fallopian tube, or peritoneal cancer, as well as those with an ancestry associated with BRCA1/2 mutations. Genetic counseling and testing are offered to those with a positive result after counseling.
A study at the George Washington University Cancer Center found a novel pathway causing platinum resistance in ovarian cancer cells. The ERK/PHD2/HIF-1α axis regulates HIF-1α stability, leading to poor prognoses for patients.
Women with BRCA1/2 gene mutations are at high risk of developing ovarian cancer, with a lifetime risk of 39-44% for BRCA1 and 11-17% for BRCA2. A new review provides guidance on screening, preventive surgery, contraception and management of menopausal symptoms to reduce this risk.
A combination of two FDA-approved drugs significantly extended the lives of mice injected with human ovarian cancer cells, altering the natural ratio of macrophages and improving survival. The treatment targets M1 macrophages, which can protect against tumor growth and progression.
Researchers will investigate loss of DNA repair mechanisms and secondary mutations leading to cancer. The goal is to develop improved cancer treatment regimens and predict drug efficacy.
Researchers at Houston Methodist and MD Anderson Cancer Center have found a new immunotherapy to treat ovarian and pancreatic cancers by blocking the action of MFAP5 protein. This protein promotes tumor growth and reduces survival rates in patients with these cancers.
Researchers at Penn State College of Medicine have identified a potential therapeutic target for high-grade serous ovarian cancer cells by preventing a protein from doing its job. Inhibiting this protein led to a halt in cell division and may be an effective strategy for future therapies.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers at CRCHUM found that Ran protein is essential for ovarian cancer cells to migrate and invade healthy tissues. Inhibiting Ran expression can break down RhoA, a protein necessary for cell migration, leading to a loss of cancer cells' ability to move.
A new biomarker test developed by researchers at Uppsala University and Sahlgrenska Academy can detect women without cancer, reducing unnecessary surgery. The test has a high accuracy rate of one in three cases, increasing the detection of early stages and borderline cases.
A study by Columbia University researchers found that limiting ovarian cancer surgery to high-volume hospitals could improve survival but also reduce access for many rural and underserved patients. In fact, nearly 35% of low-volume hospitals had better-than-expected outcomes at 60 days and 51% at 2 years.
Researchers at University of Montreal Hospital Research Centre develop a two-step combination therapy to destroy cancer cells. They manipulate cellular aging to force cancer cells into senescence, then use senolysis to eliminate them. This strategy shows superior therapeutic effectiveness on ovarian cancer patients.
Researchers have identified eight protein biomarkers that enable accurate differentiation between endometrioid and high-grade serous ovarian carcinomas. This breakthrough could lead to more precise diagnosis and tailored treatment for patients, reducing the risk of undertreatment or overtreatment.
Researchers have successfully used circulating tumor DNA to monitor patient responses and find targeted treatments for ovarian cancer. The technique can detect genomic alterations in late-stage cancers, even when biopsies are difficult or impossible, and identify poor-responding patients after chemotherapy.
A recent clinical trial at the Stephenson Cancer Center found that patients with stage two, three, or four ovarian cancer can expect about 75 months of survival when their tumors are completely removed. The treatment regimen that caused fewer difficult side effects was just as effective as those with more severe side effects.
Researchers have identified 34 genes associated with an increased risk of developing the earliest stages of ovarian cancer. The study uses alternative splicing analysis to pinpoint these genes, which can help identify women at high risk and pave the way for new therapies.
Researchers at MIT have developed a novel fluorescence imaging system to improve surgery for ovarian cancer, enabling surgeons to detect and remove tumors as small as 0.3 millimeters. This technology has shown promising results in mice, with median survival rates 40% longer than those without image guidance.
A recent study found that fewer than a quarter of breast cancer patients and a third of ovarian cancer patients underwent genetic testing for cancer-associated mutations. The research, which analyzed data from over 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014, revealed substantial...
Researchers at the University of Manchester have identified a new class of drugs that can stop ovarian cancer cells from growing. The PARG inhibitors target weaknesses in DNA replication, making them sensitive to these treatments.
A new diagnostic tool has been developed to detect ovarian cancer earlier, with high sensitivity and specificity rates. The test uses liquid biopsy proteomics to identify unique protein signatures in uterine fluid, promising improved detection rates for young women at high risk of developing the disease.
A new experimental drug, 673A, targets and annihilates stem-like ovarian cancer cells that cause recurrence. The treatment, combined with chemotherapy, resulted in significantly greater survival rates in a mouse model of ovarian cancer.
Scientists at FAU create porous scaffolds using electrospinning to support ovarian follicle growth, showing promising results. The goal is to develop an ideal artificial ovary that mimics the natural environment for follicle maturity, potentially increasing fertility in cancer patients.
Researchers at the University of Kansas have developed a 'lab-on-a-chip' that can detect cancer in a minuscule amount of plasma, leading to timelier interventions and better outcomes for patients. The device uses a 3D nanoengineering method to mix and sense biological elements more efficiently, enabling faster and cheaper detection.
Researchers from the University of Sheffield discovered a compound that kills cancer cells without triggering apoptosis, making it resistant to treatment. The new drug lead is highly active against treatment-resistant cancers and may be particularly effective against ovarian cancer.
Researchers developed AI software that predicts ovarian cancer prognosis and treatment effectiveness, outperforming existing methods by up to four times. The technology can stratify patients based on CT scan texture differences, enabling personalized medicine.
A two-year study found that out of 1919 women diagnosed with non-cancerous ovarian cysts, 20% had the cysts disappear on their own, and 80% either resolved or didn't require intervention. The risk of complications from surgical removal was lower than previously thought.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
A new study describes a novel approach to suppressing chemotherapy-induced tumor growth and recurrence in ovarian cancer. Researchers developed an anti-inflammatory drug called PTUPB that blocks the release of tumor-promoting chemicals by macrophages.
Researchers discovered that ovarian cancer cells colonize the omentum after being caught in DNA 'webs' extruded by immune cells. Inhibiting NET formation reduces metastasis in mice, suggesting a new approach to limit ovarian cancer spread. This study provides insights into improving ovarian cancer treatment.
A new blood test has been developed to detect early stage ovarian cancer using a bacterial toxin, with the test detecting significant levels of cancer glycan in over 90% of women with stage 1 ovarian cancer. The test also showed 100% accuracy for later stages of the disease and has potential for simple liquid biopsy monitoring.
A new photoacoustic imaging technique may help diagnose ovarian cancer at an early stage, improving survival rates. The technology uses transvaginal ultrasound and co-registered photoacoustic tomography to reveal information about tumor angiogenesis and blood oxygen saturation.
A new study of over 72,000 women found that simple ovarian cysts are normal and extremely common, with no association to a higher risk of ovarian cancer. Simple cysts should be considered normal findings in women of any age and can be safely ignored unless symptomatic.
Researchers at the University of Arizona are working on a disposable falloposcope to detect early-stage ovarian cancer. The device aims to reduce unnecessary procedures and improve patient outcomes by providing accurate screenings for high-risk women.
A University of Guelph study has found that opening up the blood vessels to an ovarian tumour can potentially improve the effectiveness of treatment. By creating a healthy blood supply, the tumour becomes more accessible to treatment, increasing success rates.
A phase 3 SOLO-1 trial found that olaparib maintenance therapy significantly improved progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or 2 mutation. The median PFS for those who received olaparib was approximately three years longer than the placebo group.
A study of 178 countries found a strong negative correlation between family size and cancer incidence, with larger families having a protective effect against various types of cancer. The protective effects are stronger for males than females, with non-reproduction-related cancers also being involved.
Researchers found that cancer cells from the fallopian tube affect ovary's chemical signaling, leading to increased norepinephrine levels, which drive cancer cell migration. This study highlights the importance of understanding chemistry in ovarian cancer development and treatment protocols.
Researchers discovered that mutations in the ARID1A gene lead to a molecular switch in the SWI/SNF protein complex, causing an increase in BCL2 expression and promoting tumor cell survival. Inhibiting BCL2 using a small molecule inhibitor kills ovarian cancer cells resistant to EZH2 inhibition.
A new study found that daily low-dose aspirin use reduces the risk of ovarian cancer by 23 percent. In contrast, heavy use of non-aspirin NSAIDs increases the risk. The research analyzed data from over 200,000 women and confirms earlier findings about aspirin's role in reducing certain types of cancers.
A recent study published in JAMA Oncology found that low-dose aspirin (100mg or less) reduces the risk of ovarian cancer by 23% compared to non-users. Long-term heavy use of non-aspirin NSAIDs may increase this risk.